Mayo Clinic Cancer Center

Jacksonville, Florida 32224

6 studies enrolling now · 28 studies all time

What they study most

Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Advanced Cancer, Anemia, Refractory, With Excess of Blasts, B-Cell Acute Lymphoblastic Leukaemia, Bladder Cancer, Breast Cancer, CRC, Carcinoma, Pancreatic Ductal, Colorectal Cancer, Cutaneous T Cell Lymphoma, Extra-pulmonary Neuroendocrine Carcinoma

Studies at this site

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) — Recruiting now
Blinatumomab Consolidation in Real World — Recruiting now
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma — Recruiting now
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Recruiting now
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers — Recruiting now
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — Recruiting now
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 — Recruiting now
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Running, not enrolling
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients — Completed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT — Running, not enrolling
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma — Completed
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations — Paused
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma — Completed
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies — Completed
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) — Completed
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) — Completed
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) — Completed
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma — Completed
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma — Completed
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) — Completed
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma — Completed
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes — Stopped early
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic — Completed
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia — Stopped early
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab — Completed
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies — Completed